Chris Gallaher Elected as New Chairman for Pacific Edge Board
The Board of cancer diagnostics company, Pacific Edge Limited (NZX: PEB) has announced the election of Mr Chris Gallaher as Chairman, replacing Mr Chris Swann who, as previously advised, is stepping down from the Board at today’s Annual Shareholders’ Meeting.
Chris Gallaher was appointed to the Pacific Edge Board in July 2016. He is an internationally experienced senior executive, with significant financial and risk management expertise. He has held a number of senior roles, including CEO of Village Roadshow and most recently as Group Chief Financial Officer of Fulton Hogan.
Mr Gallaher said he was looking forward to stepping into the role. “Pacific Edge is an exciting company with world leading products. It has positioned itself well to win in the world’s largest healthcare market, the USA, and is gaining good traction in other markets. The company has enormous potential and is creating significant value, both for society through better health outcomes, and for our shareholders. The task for the company is to continue its growth and its delivery of that potential.”
Pacific Edge would like to acknowledge the contribution made by Chris Swann during his 11 years on the Board. During his tenure, Pacific Edge has evolved from a research organisation to a commercial entity, with a well-developed commercial strategy, market operations in New Zealand, Australia and the USA and a ‘one stop shop’ of bladder cancer diagnostic products.
Mr Swann said: “I have been privileged to be part of Pacific Edge’s journey as we have grown and built our international business. Pacific Edge is leading the way in molecular diagnostics for bladder cancer patients, and we are now seeing growing acceptance and demand for our easy to use, accurate and cost effective Cxbladder tests. I leave Pacific Edge knowing that it is in good hands, with a strong Board and an experienced and highly capable executive team.”